The current findings point to the possibility that FBLIM1 mRNA might be employed as a potential target to forecast glioma patients’ tumor stage and prognosis, as well as a novel pharmacological target to enhance treatment outcomes and to find new cancer treatments. This evidence concerns the gene FBLIM1 and central nervous system cancer.